News >

Transformative Agents Push Progress in HER2+ Breast Cancer

Caroline Seymour
Published: Friday, Aug 09, 2019

Tessa Cigler, MD, MPH, an associate professor of clinical medicine at Weill Cornell Medical College and an associate attending physician at NewYork-Presbyterian Hospital

Tessa Cigler, MD, MPH

The emergence of HER2-targeted therapies has transformed the prognosis of HER2-positive breast cancer, and each successive therapy continues to further the progress, explained Tessa Cigler, MD, MPH, in a presentation during the 2019 OncLive® State of the Science Summit on Breast Cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x